Company: ZVRA
Filing Date: 2025-05-21
Form Type: DEFA14A
Source: 0001193125-25-123973
Chunk: 2

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-21
Form: DEFA14A
Chunk 2
---
 |     | Egan-Jones further highlighted that, “…the past two years have yielded exceptional returns that have 
 outpaced both the total market (as represented by the VTI) and the S&P Biotech ETF (XBI).”           |

| 1 | Permission to use quotes from the ISS report, the Glass Lewis report, and the Egan-Jones report was neither 
 sought nor obtained.                                                                                        |

All three proxy advisors agree that Mangless’ nominees are not the right nominees for Zevra’s Board.

| • |     | ISS, in fact, stated, “…it is unclear how the dissident nominees, which include the former CEO, would                                                                                                                       
 be able to contribute without disrupting the company’s positive momentum. In other words, the facts and circumstances in this specific case suggest that there is a compelling reason to support both management nominees.” |

| • |     | ISS added, “...the board’s concerns about having a former CEO on the board and potential disruption are 
 valid.”                                                                                                 |

| • |     | Glass Lewis highlighted, “Mr. Regan has limited, dated, and unrelated public board service,” and                                    
 that “publication of certain social media activity by Mr. Regan appears to suggest something of a blithe approach to compliance...” |

| • |     | Egan-Jones questioned the relevant expertise of Mangless’ nominees, stating, “…we do not believe           
 Mr. Regan’s background in proxy solicitation offers meaningful value in the context of Zevra’s boardroom.” |

YOUR VOTE MATTERS: VOTE THE WHITEPROXY CARD TODAY Zevra’s Board of Directors urges stockholders to only use the WHITEproxy card to vote “FOR” the re-electionof Wendy Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board as Class I directors to hold office until the 2028 Annual Meeting of Stockholders. If you receive a BLUE proxy card from Mr. Mangless, please disregard. The Board strongly recommends that stockholders protect their investment in Zevra by casting their vote as soon as possible, regardless of plans to attend the Annual Meeting on May 29, 2025. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data